Mayne Pharma is a specialty pharmaceutical company listed on the ASX. They are dedicated to commercializing both branded and generic pharmaceutical products, with a strong focus on improving patient access to life-enhancing medications. With a 40-year track record of innovation and success, Mayne Pharma has developed new oral drug delivery systems that have been successfully applied in numerous products marketed worldwide.

Mayne Pharma offers a robust portfolio of branded and generic drugs in various therapeutic areas, including women's health, oncology, dermatology, and cardiology. They strive to provide patients with better, safer, and more accessible medicines. In addition to their pharmaceutical offerings, Mayne Pharma also offers contract development and manufacturing services (CDMO) for novel oral and topical dose forms.

They specialize in pharmaceutical development, analytical testing, and commercial manufacturing to clients worldwide. Not only does Mayne Pharma focus on their product portfolio, but they also prioritize sustainability. They operate their business in a sustainable manner, ensuring the safety and well-being of their employees, supporting local communities, and caring for the environment for future generations.

Overall, Mayne Pharma is committed to improving patient access to life-enhancing medications through their innovative pharmaceutical products and contract services